# Obinutuzumab in Marginal Zone Lymphoma

> **NCT03322865** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Christian Buske** · enrollment: 56 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT03322865
- **Lead sponsor:** Christian Buske
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-23
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322865, "Obinutuzumab in Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03322865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*